Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 80
- consistent
Estudios de apoyo: Basado en 5 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Adding diabetes medications to metformin improves glycemic control in adults with T2 diabetes.
Última actualización 12 de septiembre de 2026
Key finding
Time to primary failure was significantly reduced with glimepiride.
The GRADE study compared the effectiveness of four diabetes medications and found significant reductions in HbA1c levels and time to primary failure for all treatments.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The GRADE study compared the effectiveness of four diabetes medications and found significant reductions in HbA1c levels and time to primary failure for all treatments.
Clinical relevance
These findings are significant for clinicians and patients as they provide evidence that multiple diabetes medications can effectively manage blood sugar levels. Understanding the comparative effectiveness of these treatments can help healthcare providers make informed decisions about diabetes management, ultimately improving patient outcomes.
Keep in mind
Effectiveness of interventions remains unclear due to limited evidence data. Study design may not fully represent real-world clinical settings. Potential unmeasured confounders could affect results.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Deborah JW, Heidi K, Jill PC, et al. GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study). Diabetes Care. 2019;42(11):2098-2107. doi:10.2337/dc19-0901
Efectos Principales
Glimepiride significantly reduced HbA1c levels by -1.5% (p=0.01).
Sitagliptin significantly reduced HbA1c levels by -1.4% (p=0.02).
Liraglutide significantly reduced HbA1c levels by -1.6% (p=0.01).
Insulin glargine significantly reduced HbA1c levels by -1.3% (p=0.03).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Glimepiride, Insulin Glargine, Liraglutide, and 1 more and HbA1c, Time to primary failure.
This study contributes evidence to
Primary intervention
Glimepiride
Primary outcomes
- HbA1c
- Time to primary failure
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
5
Related topics
8
Evidence pairs
764
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
Sulfonylureas and HbA1c
Guardar evidencia
Relación de evidencia
DPP-4 Inhibitors and HbA1c
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTime to primary failure
Insulin Glargine → Time to primary failure
Insulin Glargine → Time to primary failure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- All medications significantly decreased HbA1c levels.
- Time to primary failure was significantly reduced for each medication.
- Effect sizes ranged from -1.2% to -1.6% in HbA1c reductions.
A quién se aplica
- Adults with type 2 diabetes.
- Patients requiring pharmacological intervention for blood sugar control.
Tener en Cuenta
- Results may not generalize to all populations with diabetes.
- Further research is needed to confirm long-term effectiveness.
- The study did not assess patient adherence to medications.
Entre Líneas
- Effectiveness of interventions remains unclear due to limited evidence data.
- Study design may not fully represent real-world clinical settings.
- Potential unmeasured confounders could affect results.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Sulfonylureas and HbA1c, GLP-1 Receptor Agonists and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Sulfonylureas → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 80
- consistent
Estudios de apoyo: Basado en 5 estudios
View evidenceMedications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 7 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
5 studies
outcome_hubMeasures HbA1c as a key outcome.
Sulfonylureas Evidence Hub
All studies on Sulfonylureas
5 studies
intervention_hubContributes to Sulfonylureas evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Glimepiride and HbA1c
Intervention: GlimepirideOutcome: HbA1c
5 results
All studies on Liraglutide and HbA1c
Intervention: LiraglutideOutcome: HbA1c
7 results
All studies on Glimepiride
Intervention: Glimepiride
5 results
All studies on Liraglutide
Intervention: Liraglutide
7 results
All studies measuring HbA1c
Outcome: HbA1c
5 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do Sulfonylureas lower HbA1c?
Strong Evidence
Sulfonylureas may lower HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.2 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Do DPP-4 Inhibitors lower HbA1c?
Strong Evidence
DPP-4 Inhibitors appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Does Glimepiride improve time to primary failure?
Emerging Evidence
Glimepiride appears to improve time to primary failure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Time to primary failure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsLiraglutide improves metabolic changes in type 2 diabetes.GLP-1RA improves metabolic outcomes in MASLDSitagliptin improves kidney function in type 1 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.